{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:24:05Z","timestamp":1774351445367,"version":"3.50.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s41669-025-00636-5","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:09:15Z","timestamp":1768370955000},"page":"249-263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-Effectiveness of RefluxStop Versus Nissen Fundoplication and Proton Pump Inhibitors for Refractory Gastroesophageal Reflux Disease: A Spanish Healthcare Perspective"],"prefix":"10.1007","volume":"10","author":[{"given":"Sam","family":"Harper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9254-5207","authenticated-orcid":false,"given":"Khanh Ha","family":"Bui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Mealing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo Priego","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Moreno","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"issue":"24","key":"636_CR1","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1001\/jama.2020.21360","volume":"324","author":"J Maret-Ouda","year":"2020","unstructured":"Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal. JAMA. 2020;324(24):2536\u201347.","journal-title":"JAMA"},{"issue":"18","key":"636_CR2","doi-asserted-by":"publisher","first-page":"5383","DOI":"10.3390\/jcm11185383","volume":"11","author":"T Voulgaris","year":"2022","unstructured":"Voulgaris T, Lekakis V, Orfanidou A, Vlachogiannakos J, Kamberoglou D, Papatheodoridis G, Karamanolis G. The Lyon Consensus Criteria for GERD diagnosis in a Greek population: the clinical impact and changes in GERD diagnosis in a real-world, Retrospective Study. J Clin Med. 2022;11(18):5383. https:\/\/doi.org\/10.3390\/jcm11185383.","journal-title":"J Clin Med."},{"issue":"6","key":"636_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1136\/gutjnl-2012-304269","volume":"63","author":"HB El-Serag","year":"2014","unstructured":"El-Serag HB, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871\u201380.","journal-title":"Gut"},{"issue":"1","key":"636_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1365-2036.2006.02733.x","volume":"23","author":"J Ponce","year":"2006","unstructured":"Ponce J, et al. Prevalence of gastro-oesophageal reflux disease in Spain and associated factors. Aliment Pharmacol Ther. 2006;23(1):175\u201384.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"636_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1586\/egh.12.61","volume":"7","author":"C Martin-de-Argila","year":"2013","unstructured":"Martin-de-Argila C, Martinez-Jimenez P. Epidemiological study on the incidence of gastroesophageal reflux disease symptoms in patients in acute treatment with NSAIDs. Expert Rev Gastroenterol Hepatol. 2013;7(1):27\u201333.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"636_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1046\/j.1365-2036.2003.01769.x","volume":"19","author":"M Diaz-Rubio","year":"2004","unstructured":"Diaz-Rubio M, et al. Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population. Aliment Pharmacol Ther. 2004;19(1):95\u2013105.","journal-title":"Aliment Pharmacol Ther"},{"key":"636_CR7","unstructured":"Hockley T, Darba J. Europe\u2019s lost patients. untreated and poorly treated gastroesophageal reflux disease (GERD). In: Hockley T, editor. Barcelona: Policy Analysis Centre; 2008. http:\/\/www.sefap.it\/servizi_letteraturacardio_200902\/GERD.pdf. Accessed: 8 Dec 2025."},{"issue":"3","key":"636_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000081626","volume":"70","author":"E Rey","year":"2004","unstructured":"Rey E, et al. Medical consultation for gastro-oesophageal reflux symptoms: reasons and associated factors. Digestion. 2004;70(3):173\u20137.","journal-title":"Digestion"},{"issue":"7","key":"636_CR9","doi-asserted-by":"publisher","first-page":"518","DOI":"10.4321\/S1130-01082006000700005","volume":"98","author":"E Rey","year":"2006","unstructured":"Rey E, et al. Impact of gastroesophageal reflux symptoms on health resource usage and work absenteeism in Spain. Rev Esp Enferm Dig. 2006;98(7):518\u201326.","journal-title":"Rev Esp Enferm Dig"},{"issue":"3","key":"636_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2165\/11531670-000000000-00000","volume":"30","author":"S Toghanian","year":"2010","unstructured":"Toghanian S, et al. The burden of disrupting gastro-oesophageal reflux disease: a database study in US and European cohorts. Clin Drug Investig. 2010;30(3):167\u201378.","journal-title":"Clin Drug Investig"},{"issue":"11","key":"636_CR11","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1097\/MEG.0b013e32832a7d9b","volume":"21","author":"JA Ferrus","year":"2009","unstructured":"Ferrus JA, et al. Management of gastroesophageal reflux disease in primary care settings in Spain: SYMPATHY I study. Eur J Gastroenterol Hepatol. 2009;21(11):1269\u201378.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"15","key":"636_CR12","doi-asserted-by":"publisher","first-page":"892","DOI":"10.12998\/wjcc.v6.i15.892","volume":"6","author":"S Klenzak","year":"2018","unstructured":"Klenzak S, et al. Management of gastroesophageal reflux disease: patient and physician communication challenges and shared decision making. World J Clin Cases. 2018;6(15):892\u2013900.","journal-title":"World J Clin Cases"},{"issue":"15","key":"636_CR13","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1001\/jama.287.15.1972","volume":"287","author":"N Shaheen","year":"2002","unstructured":"Shaheen N, Ransohoff DF. Gastroesophageal reflux, arrett esophagus, and esophageal cancer: scientific review. JAMA. 2002;287(15):1972\u201381.","journal-title":"JAMA"},{"issue":"43","key":"636_CR14","doi-asserted-by":"publisher","first-page":"6216","DOI":"10.3748\/wjg.v18.i43.6216","volume":"18","author":"GD De Palma","year":"2012","unstructured":"De Palma GD. Management strategies of Barrett\u2019s esophagus. World J Gastroenterol. 2012;18(43):6216\u201325.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"636_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1586\/erp.11.5","volume":"11","author":"J Darb\u00e0","year":"2011","unstructured":"Darb\u00e0 J, et al. Epidemiology and societal costs of gastroesophageal reflux disease and Barrett\u2019s syndrome in Germany, Italy and Spain. Expert Rev Pharmacoecon Outcomes Res. 2011;11(2):225\u201332.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"Suppl 6","key":"636_CR16","doi-asserted-by":"publisher","first-page":"S430","DOI":"10.21037\/jtd.2017.04.59","volume":"9","author":"P Avanzas","year":"2017","unstructured":"Avanzas P, Pascual I, Moris C. The great challenge of the public health system in Spain. J Thorac Dis. 2017;9(Suppl 6):S430\u20133.","journal-title":"J Thorac Dis"},{"issue":"2","key":"636_CR17","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00464-022-09817-3","volume":"37","author":"BJ Slater","year":"2023","unstructured":"Slater BJ, et al. Multi-society consensus conference and guideline on the treatment of gastroesophageal reflux disease (GERD). Surg Endosc. 2023;37(2):781\u2013806.","journal-title":"Surg Endosc"},{"key":"636_CR18","unstructured":"Javier Alcedo CC, Balboa A, Serra J, Murzi-Pulgar M, Guarner-Argente C, Mas P, M\u00ednguez M, Rey E, Estremera F, Mearin F, Montoro M. Update document of the on 2024."},{"issue":"1","key":"636_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","volume":"117","author":"PO Katz","year":"2022","unstructured":"Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117(1):27\u201356. https:\/\/doi.org\/10.14309\/ajg.0000000000001538.","journal-title":"Am J Gastroenterol."},{"issue":"1","key":"636_CR20","volume":"16","author":"MS Bhatnagar","year":"2024","unstructured":"Bhatnagar MS, et al. Long-term the. Cureus. 2024;16(1):e52773.","journal-title":"Cureus"},{"issue":"9","key":"636_CR21","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00228-023-03534-z","volume":"79","author":"LGT Shanika","year":"2023","unstructured":"Shanika LGT, et al. Proton pump inhibitor use: systematic review of global trends and practices. Eur J Clin Pharmacol. 2023;79(9):1159\u201372.","journal-title":"Eur J Clin Pharmacol"},{"key":"636_CR22","doi-asserted-by":"publisher","first-page":"goad008","DOI":"10.1093\/gastro\/goad008","volume":"11","author":"T Lata","year":"2023","unstructured":"Lata T, et al. Current management of gastro-oesophageal reflux disease-treatment costs, safety profile, and effectiveness: a narrative review. Gastroenterol Rep (Oxf). 2023;11:goad008.","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"8","key":"636_CR23","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/ajg.2016.166","volume":"111","author":"A Lanas","year":"2016","unstructured":"Lanas A. We, and to. Am J Gastroenterol. 2016;111(8):1085\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"636_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.2174\/157488410793352067","volume":"5","author":"E Ramirez","year":"2010","unstructured":"Ramirez E, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol. 2010;5(4):288\u201397.","journal-title":"Curr Clin Pharmacol"},{"issue":"4","key":"636_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.17235\/reed.2016.4232\/2016","volume":"108","author":"C de la Coba Ortiz","year":"2016","unstructured":"de la Coba Ortiz C, et al. Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Espanola de Patologia Digestiva. Rev Esp Enferm Dig. 2016;108(4):207\u201324.","journal-title":"Rev Esp Enferm Dig"},{"issue":"1","key":"636_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13217-6","volume":"22","author":"F Torres-Bondia","year":"2022","unstructured":"Torres-Bondia F, et al. Evolution of the consumption trend of proton pump inhibitors in the Lleida Health Region between 2002 and 2015. BMC Public Health. 2022;22(1):818.","journal-title":"BMC Public Health"},{"issue":"9","key":"636_CR27","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1002\/bjs.7174","volume":"97","author":"JA Broeders","year":"2010","unstructured":"Broeders JA, et al. Systematic review and meta-analysis of laparoscopic Nissen (posterior total) versus Toupet (posterior partial) fundoplication for gastro-oesophageal reflux disease. Br J Surg. 2010;97(9):1318\u201330.","journal-title":"Br J Surg"},{"issue":"5","key":"636_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.cgh.2012.12.006","volume":"11","author":"JE Richter","year":"2013","unstructured":"Richter JE. Gastroesophageal reflux disease treatment: side effects and complications of fundoplication. Clin Gastroenterol Hepatol. 2013;11(5):465\u201371 (quiz e39).","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"636_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/01.sla.0000217667.55939.64","volume":"244","author":"WA Draaisma","year":"2006","unstructured":"Draaisma WA, et al. Five-year subjective and objective results of laparoscopic and conventional Nissen fundoplication: a randomized trial. Ann Surg. 2006;244(1):34\u201341.","journal-title":"Ann Surg"},{"issue":"56","key":"636_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10353-024-00836-z","volume":"2024","author":"J Zehetner","year":"2024","unstructured":"Zehetner J, Hoffsten J, Das S, et al. Looking back on a gold standard: a systematic literature review of laparoscopic Nissen fundoplication as an anti-reflux treatment option. Eur Surg. 2024;2024(56):143\u201371. https:\/\/doi.org\/10.1007\/s10353-024-00836-z.","journal-title":"Eur Surg."},{"issue":"1","key":"636_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12893-020-00794-9","volume":"20","author":"M Bjelovi\u0107","year":"2020","unstructured":"Bjelovi\u0107 M, et al. Non-active implantable device treating acid reflux with a new dynamic treatment approach: 1-year results. BMC Surg. 2020;20(1):159.","journal-title":"BMC Surg"},{"issue":"10","key":"636_CR32","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1007\/s00464-024-11114-0","volume":"38","author":"L Hars\u00e1nyi","year":"2024","unstructured":"Hars\u00e1nyi L, et al. Treating acid reflux without compressing the food passageway: 4-year safety and clinical outcomes with the RefluxStop device in a prospective multicenter study. Surg Endosc. 2024;38(10):6060\u20139.","journal-title":"Surg Endosc"},{"issue":"7","key":"636_CR33","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1007\/s00464-025-11818-x","volume":"39","author":"L Harsanyi","year":"2025","unstructured":"Harsanyi L, et al. Food passageway-related sequelae in the RefluxStop prospective multicenter trial: patient-centric outcomes of dysphagia, odynophagia, gas-bloating, and inability to belch and\/or vomit at 5 years. Surg Endosc. 2025;39(7):4615\u201327.","journal-title":"Surg Endosc"},{"issue":"2","key":"636_CR34","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/bjs.4762","volume":"92","author":"R Ludemann","year":"2005","unstructured":"Ludemann R, et al. Five-year follow-up of a randomized clinical trial of laparoscopic total versus anterior 180 degrees fundoplication. Br J Surg. 2005;92(2):240\u20133.","journal-title":"Br J Surg"},{"issue":"1","key":"636_CR35","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/13696998.2023.2201063","volume":"26","author":"S Harper","year":"2023","unstructured":"Harper S, et al. Cost-effectiveness of a novel, non-active implantable device as a treatment for refractory gastro-esophageal reflux disease. J Med Econ. 2023;26(1):603\u201313.","journal-title":"J Med Econ"},{"issue":"1","key":"636_CR36","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/13696998.2024.2362564","volume":"27","author":"S Harper","year":"2024","unstructured":"Harper S, et al. Cost-effectiveness of the RefluxStop device for management of refractory gastroesophageal reflux disease in Switzerland. J Med Econ. 2024;27(1):805\u201315.","journal-title":"J Med Econ"},{"issue":"1","key":"636_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12962-025-00665-1","volume":"23","author":"S Harper","year":"2025","unstructured":"Harper S, et al. Cost-effectiveness of RefluxStop compared to proton pump inhibitors and Nissen fundoplication for management of persistent gastroesophageal reflux disease in Norway. Cost Eff Resour Alloc. 2025;23(1):63. https:\/\/doi.org\/10.1186\/s12962-025-00665-1. (Published 2025 Oct 29).","journal-title":"Cost Eff Resour Alloc."},{"key":"636_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2024.2417774","author":"S Harper","year":"2024","unstructured":"Harper S, Kartha M, Mealing S, Lundell L. A cost-effectiveness analysis of RefluxStop against relevant therapeutic alternatives for chronic gastroesophageal reflux disease in Sweden. Expert Rev Pharmacoecon Outcomes Res. 2024. https:\/\/doi.org\/10.1080\/14737167.2024.2417774.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"issue":"7","key":"636_CR39","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40273-018-0672-z","volume":"36","author":"AE Attema","year":"2018","unstructured":"Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations. Pharmacoeconomics. 2018;36(7):745\u201358.","journal-title":"Pharmacoeconomics"},{"key":"636_CR40","doi-asserted-by":"crossref","unstructured":"Grant A, et al. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease\u2014a UK collaborative study. The REFLUX trial. Health Technol Assess. 2008;12(31):1\u2013181, iii\u2013iv.","DOI":"10.3310\/hta12310"},{"issue":"16","key":"636_CR41","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1811424","volume":"381","author":"SJ Spechler","year":"2019","unstructured":"Spechler SJ, et al. Randomized trial of medical versus surgical treatment for refractory heartburn. N Engl J Med. 2019;381(16):1513\u201323.","journal-title":"N Engl J Med"},{"key":"636_CR42","doi-asserted-by":"crossref","unstructured":"Hars\u00e1nyi L, Kincses Z, Altorjay \u00c1. Acid reflux management with the RefluxStop implant: a prospective multicenter trial with 3-year outcomes. Digest Dis Sci. 2024. (accepted for publication).","DOI":"10.1007\/s10620-024-08788-w"},{"issue":"35","key":"636_CR43","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.3748\/wjg.v23.i35.6500","volume":"23","author":"A Trifan","year":"2017","unstructured":"Trifan A, et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: ystematic review and meta-analysis. World J Gastroenterol. 2017;23(35):6500\u201315.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"636_CR44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.11005\/jbm.2018.25.3.141","volume":"25","author":"Y Nassar","year":"2018","unstructured":"Nassar Y, Richter S. Proton-pump and and -analysis. J Bone Metab. 2018;25(3):141\u201351.","journal-title":"J Bone Metab"},{"issue":"5","key":"636_CR45","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/intqhc\/mzaa041","volume":"32","author":"PA Nguyen","year":"2020","unstructured":"Nguyen PA, et al. Meta-analysis of proton pump inhibitors induced risk of community-acquired pneumonia. Int J Qual Health Care. 2020;32(5):292\u20139.","journal-title":"Int J Qual Health Care"},{"issue":"13","key":"636_CR46","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3390\/cancers14133052","volume":"14","author":"TN Poly","year":"2022","unstructured":"Poly TN, Lin MC, Syed-Abdul S, Huang CW, Yang HC, Li YJ. Proton pump inhibitor use and risk of gastric cancer: current evidence from epidemiological studies and critical appraisal. Cancers (Basel). 2022;14(13):3052. https:\/\/doi.org\/10.3390\/cancers14133052.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"636_CR47","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/ndt\/gfw470","volume":"33","author":"S Nochaiwong","year":"2018","unstructured":"Nochaiwong S, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018;33(2):331\u201342.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"636_CR48","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/apt.14955","volume":"48","author":"R Batchelor","year":"2018","unstructured":"Batchelor R, et al. Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel. Aliment Pharmacol Ther. 2018;48(8):780\u201396.","journal-title":"Aliment Pharmacol Ther"},{"key":"636_CR49","unstructured":"National Institute for Health and Care Excellence (NICE). Dyspepsia and gastro-oesophageal reflux disease. Appendix H: Full Health Economics Report. 2014. [5 May 2023]. Available from: https:\/\/www.nice.org.uk\/guidance\/cg184\/evidence\/appendix-h-full-health-economics-report-pdf-6955335252."},{"issue":"3","key":"636_CR50","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/aje\/kwn121","volume":"168","author":"F Yousef","year":"2008","unstructured":"Yousef F, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett\u2019s esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168(3):237\u201349.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"636_CR51","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.hlc.2017.10.020","volume":"27","author":"TP Shiraev","year":"2018","unstructured":"Shiraev TP, Bullen A. <article-title update=\"added\">Proton pump inhibitors and cardiovascular events: a systematic review. Heart Lung Circ. 2018;27(4):443\u201350.","journal-title":"Heart Lung Circ"},{"issue":"10","key":"636_CR52","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2165\/00019053-200725100-00003","volume":"25","author":"L Bojke","year":"2007","unstructured":"Bojke L, Hornby E, Sculpher M. A comparison of the cost effectiveness of pharmacotherapy or surgery (laparoscopic fundoplication) in the treatment of GORD. Pharmacoeconomics. 2007;25(10):829\u201341.","journal-title":"Pharmacoeconomics"},{"key":"636_CR53","unstructured":"Szende A, et al. Self-1 ed. Dordrecht: Springer; 2014."},{"key":"636_CR54","unstructured":"Registry of Discharges from General Hospitals of the National Health System. CMBD. State Standard. 2024. [cited 2024 December 5]. Available from: https:\/\/www.sanidad.gob.es\/estadEstudios\/estadisticas\/cmbd.htm."},{"key":"636_CR55","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1332\/174426410X482999","volume":"6","author":"I Shemilt","year":"2010","unstructured":"Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy A J Res Debate Pract. 2010;6:51\u201360.","journal-title":"Evid Policy A J Res Debate Pract"},{"key":"636_CR56","unstructured":"BotPlus (General Counsel of the Association of Pharmacists). Spanish Agency for Medicines and Health Products (AEMPS). 2024. [cited 2024 December 5]. Available from: https:\/\/botplusweb.farmaceuticos.com\/."},{"issue":"5","key":"636_CR57","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/03007995.2018.1552407","volume":"35","author":"V Pollit","year":"2019","unstructured":"Pollit V, et al. A cost-effectiveness analysis of endoscopic eradication therapy for management of dysplasia arising in patients with Barrett\u2019s oesophagus in the United Kingdom. Curr Med Res Opin. 2019;35(5):805\u201315.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"636_CR58","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40273-021-01112-8","volume":"40","author":"D Husereau","year":"2022","unstructured":"Husereau D, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) for. Pharmacoeconomics. 2022;40(6):601\u20139.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"636_CR59","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/hec.3633","volume":"27","author":"L Vallejo-Torres","year":"2018","unstructured":"Vallejo-Torres L, Garc\u00eda-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018;27(4):746\u201361.","journal-title":"Health Econ"},{"key":"636_CR60","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13643-015-0181-5","volume":"5","author":"F Catala-Lopez","year":"2016","unstructured":"Catala-Lopez F, et al. The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review. Syst Rev. 2016;5:6.","journal-title":"Syst Rev"},{"key":"636_CR61","doi-asserted-by":"publisher","first-page":"S1284","DOI":"10.14309\/00000434-201610001-02530","volume":"111","author":"B Shahid","year":"2016","unstructured":"Shahid B. Educational to of. Off J Am Coll Gastroenterol | ACG. 2016;111:S1284.","journal-title":"Off J Am Coll Gastroenterol | ACG"},{"key":"636_CR62","unstructured":"Seeras K, Bittar K, Siccardi M. Nissen fundoplication. [Updated 2023 July 17]. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2024 Jan-. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519521\/. Accessed on 1 July 2024."},{"issue":"1","key":"636_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.36469\/jheor.2024.90924","volume":"11","author":"S Harper","year":"2024","unstructured":"Harper S, et al. Budget mpact of RefluxStop\u2122 as a for with -oesophageal in the United Kingdom. J Health Econ Outcomes Res. 2024;11(1):1\u20137.","journal-title":"J Health Econ Outcomes Res"},{"key":"636_CR64","unstructured":"Harper S, et al. The of RefluxStop for on the Italian. PharmacoEconomics \u2013 Open. 2024."},{"key":"636_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-10-9","volume":"10","author":"JA Cook","year":"2009","unstructured":"Cook JA. The challenges faced in the design, conduct and analysis of surgical randomised controlled trials. Trials. 2009;10:9.","journal-title":"Trials"},{"issue":"5","key":"636_CR66","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/clpt.2013.13","volume":"93","author":"JC Bouvy","year":"2013","unstructured":"Bouvy JC, et al. The cost-effectiveness of periodic safety update reports for biologicals in Europe. Clin Pharmacol Ther. 2013;93(5):433\u201342.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"636_CR67","doi-asserted-by":"publisher","first-page":"e1332","DOI":"10.1016\/S2214-109X(19)30318-3","volume":"7","author":"WHO CVD Risk Chart Working Group","year":"2019","unstructured":"WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7(10):e1332\u201345.","journal-title":"Lancet Glob Health"},{"issue":"597","key":"636_CR68","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.3399\/bjgp12X636065","volume":"62","author":"G Collins","year":"2012","unstructured":"Collins G, Altman D. Predicting the risk of chronic kidney disease in the UK: an evaluation of QKidney\u00ae scores using a primary care database. Br J Gen Pract. 2012;62(597):e243\u201350.","journal-title":"Br J Gen Pract"},{"issue":"1","key":"636_CR69","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cegh.2017.12.008","volume":"7","author":"SS Hussain","year":"2019","unstructured":"Hussain SS, Habib A, Najmi AK. Proton pump inhibitors use and risk of chronic kidney disease: evidence-based meta-analysis of observational studies. Clin Epidemiol Glob Health. 2019;7(1):46\u201352.","journal-title":"Clin Epidemiol Glob Health"},{"issue":"4","key":"636_CR70","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385\u201397.","journal-title":"Osteoporos Int"},{"issue":"1","key":"636_CR71","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00198-015-3365-x","volume":"27","author":"B Zhou","year":"2016","unstructured":"Zhou B, et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339\u201347.","journal-title":"Osteoporos Int"},{"key":"636_CR72","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268819001559","volume":"147","author":"X Sun","year":"2019","unstructured":"Sun X, Douiri A, Gulliford M. Pneumonia incidence trends in UK primary care from 2002 to 2017: population-based cohort study. Epidemiol Infect. 2019;147:e263.","journal-title":"Epidemiol Infect"},{"issue":"6","key":"636_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128004","volume":"10","author":"AA Lambert","year":"2015","unstructured":"Lambert AA, et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS ONE. 2015;10(6):e0128004.","journal-title":"PLoS ONE"},{"key":"636_CR74","unstructured":"Public Health England. Clostridium difficile infection: mandatory surveillance 2017\/18. 2018. [5 May 2023]. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/724368\/CDI_summary_2018.pdf."},{"issue":"7","key":"636_CR75","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/ajg.2012.179","volume":"107","author":"S Janarthanan","year":"2012","unstructured":"Janarthanan S, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001\u201310.","journal-title":"Am J Gastroenterol"},{"key":"636_CR76","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.canep.2018.02.004","volume":"53","author":"N Brusselaers","year":"2018","unstructured":"Brusselaers N, Engstrand L, Lagergren J. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol. 2018;53:172\u20137.","journal-title":"Cancer Epidemiol"},{"issue":"8","key":"636_CR77","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1007\/s00464-016-5370-3","volume":"31","author":"D Skubleny","year":"2017","unstructured":"Skubleny D, et al. LINX(\u00ae) magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis. Surg Endosc. 2017;31(8):3078\u201384.","journal-title":"Surg Endosc"},{"issue":"8","key":"636_CR78","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1007\/s11605-018-3775-0","volume":"22","author":"ET Alicuben","year":"2018","unstructured":"Alicuben ET, et al. Worldwide xperience with of the. J Gastrointest Surg. 2018;22(8):1442\u20137.","journal-title":"J Gastrointest Surg"},{"issue":"5","key":"636_CR79","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s00464-002-8568-5","volume":"17","author":"WG Ainslie","year":"2003","unstructured":"Ainslie WG, et al. Micropuncture cholecystectomy vs conventional laparoscopic cholecystectomy: a randomized controlled trial. Surg Endosc. 2003;17(5):766\u201372.","journal-title":"Surg Endosc"},{"issue":"1","key":"636_CR80","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/13696998.2021.1917139","volume":"24","author":"MA Chaudhary","year":"2021","unstructured":"Chaudhary MA, et al. Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data. J Med Econ. 2021;24(1):607\u201319.","journal-title":"J Med Econ"},{"issue":"7","key":"636_CR81","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1007\/s00464-018-6038-y","volume":"32","author":"TR Palser","year":"2018","unstructured":"Palser TR, et al. Variation in laparoscopic anti-reflux surgery across England: a 5-year review. Surg Endosc. 2018;32(7):3208\u201314.","journal-title":"Surg Endosc"},{"issue":"3","key":"636_CR82","first-page":"145","volume":"110","author":"JM Esteban","year":"2018","unstructured":"Esteban JM, et al. Economic evaluation of endoscopic radiofrequency ablation for the treatment of dysplastic Barrett\u2019s esophagus in Spain. Rev Esp Enferm Dig. 2018;110(3):145\u201354.","journal-title":"Rev Esp Enferm Dig"},{"key":"636_CR83","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12913-016-1297-6","volume":"16","author":"J Corral","year":"2016","unstructured":"Corral J, et al. Long-term costs of colorectal cancer treatment in Spain. BMC Health Serv Res. 2016;16:56.","journal-title":"BMC Health Serv Res"},{"key":"636_CR84","doi-asserted-by":"crossref","unstructured":"Kerr M, et al. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant. 2012;27(Suppl 3):iii73\u201380.","DOI":"10.1093\/ndt\/gfs269"},{"issue":"1","key":"636_CR85","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/vaccines10010059","volume":"10","author":"F L\u00f3pez","year":"2021","unstructured":"L\u00f3pez F, Catal\u00e0 M, Prats C, Estrada O, Oliva I, Prat N, Isnard M, Vall\u00e8s R, Vilar M, Clotet B, Argimon JM, Aran A, Ara J. A cost-benefit analysis of COVID-19 vaccination in Catalonia. Vaccines (Basel). 2021;10(1):59. https:\/\/doi.org\/10.3390\/vaccines10010059.","journal-title":"Vaccines (Basel)."},{"issue":"1","key":"636_CR86","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1186\/s12913-021-06566-2","volume":"21","author":"C Escobar","year":"2021","unstructured":"Escobar C, et al. Costs and healthcare utilisation of patients with chronic kidney disease in Spain. BMC Health Serv Res. 2021;21(1):536.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"636_CR87","first-page":"656","volume":"31","author":"JM Lamas Barreiro","year":"2011","unstructured":"Lamas Barreiro JM, et al. Costs and added value of haemodialysis and peritoneal dialysis outsourcing agreements. Nefrologia. 2011;31(6):656\u201363.","journal-title":"Nefrologia"},{"issue":"11","key":"636_CR88","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1093\/ndt\/gfr088","volume":"26","author":"G Villa","year":"2011","unstructured":"Villa G, et al. Cost analysis of the Spanish renal replacement therapy programme. Nephrol Dial Transplant. 2011;26(11):3709\u201314.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"636_CR89","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1186\/s12913-020-05828-9","volume":"20","author":"C Escobar","year":"2020","unstructured":"Escobar C, et al. Costs and healthcare utilisation of patients with heart failure in Spain. BMC Health Serv Res. 2020;20(1):964.","journal-title":"BMC Health Serv Res"},{"key":"636_CR90","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2147\/CEOR.S350790","volume":"14","author":"A Naranjo","year":"2022","unstructured":"Naranjo A, et al. Cost-effectiveness analysis of fracture liaison services compared with standard of care in the secondary prevention of fragility fractures in Spain. Clinicoecon Outcomes Res. 2022;14:249\u201364.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"11","key":"636_CR91","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jval.2019.06.011","volume":"22","author":"T Shiri","year":"2019","unstructured":"Shiri T, et al. Pneumococcal of, and of. Value Health. 2019;22(11):1329\u201344.","journal-title":"Value Health"},{"key":"636_CR92","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ijid.2015.05.013","volume":"36","author":"A Asensio","year":"2015","unstructured":"Asensio A, et al. The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study. Int J Infect Dis. 2015;36:31\u20138.","journal-title":"Int J Infect Dis"},{"key":"636_CR93","unstructured":"National Institute for Health and Care Excellence (NICE). Technology appraisal guidance [TA378]: remucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy. 2016. [5 May 2023]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta378."},{"issue":"11","key":"636_CR94","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012977","volume":"6","author":"M Laudicella","year":"2016","unstructured":"Laudicella M, et al. Impact of laparoscopic versus open surgery on hospital costs for colon cancer: a population-based retrospective cohort study. BMJ Open. 2016;6(11):e012977.","journal-title":"BMJ Open"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00636-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00636-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00636-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:04:05Z","timestamp":1773846245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00636-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["636"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00636-5","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sam Harper and Stuart Mealing are employed by a consultancy company (York Health Economics Consortium at the University of York, UK) that was commissioned by Implantica to develop the model. Khanh Ha Bui is an employee of Implantica. Daniel Sanchez, Pablo Priego Jim\u00e9nez, and Carlos Moreno Sanz do not have personal conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Since no individual patient level data was collected, and the Markov model was built using aggregated data from published literature, there was no ethical approval required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data supporting the findings of this study are available within the paper.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"The model is not available as open source because it contains confidential scientific and business information and supports ongoing regulatory and commercialization efforts. The authors anticipate being able to share further details in the future once these activities conclude. The corresponding author is available to assist readers with any further inquiries pertaining to methodological, data, and analytical aspects of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Sam Harper, Khanh Ha Bui, and Stuart Mealing designed and developed the model. Daniel Sanchez, Pablo Priego Jim\u00e9nez, and Carlos Moreno Sanz contributed to the design of the economic model and provided clinical perspective to validate the results. All authors contributed to the manuscript and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Data from this manuscript have been presented at the ISPOR Europe 2024.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous Presentations"}}]}}